{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:49:43Z","timestamp":1787028583933,"version":"build-2736575974"},"reference-count":34,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T00:00:00Z","timestamp":1755388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Regione Campania","award":["303"],"award-info":[{"award-number":["303"]}]},{"name":"Novartis Gene Therapies (Zurich, Switzerland)","award":["303"],"award-info":[{"award-number":["303"]}]},{"name":"CEINGE\u2013Biotecnologie Avanzate Franco Salvatore s.c. a r.l.","award":["303"],"award-info":[{"award-number":["303"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJNS"],"abstract":"<jats:p>Three targeted therapies are currently available for spinal muscular atrophy (SMA), which have dramatically changed the natural history of this severe and potentially fatal disease. More than 95% of SMA cases have a homozygous deletion of exon 7 of the SMN1 gene. Disease expression mainly depends on the copy number of SMN2, a hypomorphic copy of SMN1. Many countries in the world have implemented newborn screening (NBS) programs for early identification and treatment of children with SMA. We herein present the first two-year results of the SMA NBS program in Campania, a region with one of the highest birth rates in Italy. Genomic DNA was extracted from dried blood spots (DBS) and peripheral blood. For DBS, the SMN1 gene copy number was evaluated by quantitative polymerase chain reaction (qPCR) targeting SMN1 exon 7 and a reference gene (RPP30). In positive newborns and their parents, SMN1\/SMN2 copies were evaluated by multiplex ligation probe amplification (MLPA). We analyzed 77,945 newborns and identified 11 positive children. Six patients had 2 copies of SMN2, but only one showed severe SMA-related signs at birth. Eligible newborns were treated with gene therapy within 20 days of birth. Notably, qPCR failed to amplify the reference RPP30 gene in 10\/77,945 DBS. Despite this limitation, we observed that about 1\/40 DBS had \u0394Ct values consistent with the presence of one SMN1 copy. The semi-automated procedure used for SMA NBS showed excellent performance in detecting the presence of homozygous deletion of SMN1 exon 7, with the exception of a few cases with the absence of amplification of the reference gene. By solving this limitation, the screening procedure has the potential to detect heterozygous carriers of the SMN1 deletion and, consequently, identify families at procreative risk of SMA.<\/jats:p>","DOI":"10.3390\/ijns11030064","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T15:34:53Z","timestamp":1755531293000},"page":"64","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Newborn Screening Program for Spinal Muscular Atrophy in the Campania Region (Italy): Current Limitations and Potential Perspectives"],"prefix":"10.3390","volume":"11","author":[{"given":"Adelaide","family":"Ambrosio","sequence":"first","affiliation":[{"name":"CEINGE Advanced Biotechnologies Franco Salvatore, s.c.a r.l., 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Fioretti","sequence":"additional","affiliation":[{"name":"CEINGE Advanced Biotechnologies Franco Salvatore, s.c.a r.l., 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"D\u2019Andrea","sequence":"additional","affiliation":[{"name":"CEINGE Advanced Biotechnologies Franco Salvatore, s.c.a r.l., 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pezone","sequence":"additional","affiliation":[{"name":"CEINGE Advanced Biotechnologies Franco Salvatore, s.c.a r.l., 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Bitetti","sequence":"additional","affiliation":[{"name":"Neurology Unit, Santobono-Pausilipon Children Hospital, 80122 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Di Domenico","sequence":"additional","affiliation":[{"name":"CEINGE Advanced Biotechnologies Franco Salvatore, s.c.a r.l., 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Vallone","sequence":"additional","affiliation":[{"name":"CEINGE Advanced Biotechnologies Franco Salvatore, s.c.a r.l., 80145 Naples, Italy"},{"name":"Integrated Care Department of Laboratory and Transfusion Medicine, University Hospital Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Maiolo","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Medical Biotechnologies, School of Medicine, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Cioce","sequence":"additional","affiliation":[{"name":"Integrated Care Department of Laboratory and Transfusion Medicine, University Hospital Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Giustino","sequence":"additional","affiliation":[{"name":"CEINGE Advanced Biotechnologies Franco Salvatore, s.c.a r.l., 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Varone","sequence":"additional","affiliation":[{"name":"Neurology Unit, Santobono-Pausilipon Children Hospital, 80122 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4255-7312","authenticated-orcid":false,"given":"Gabriella","family":"Esposito","sequence":"additional","affiliation":[{"name":"CEINGE Advanced Biotechnologies Franco Salvatore, s.c.a r.l., 80145 Naples, Italy"},{"name":"Department of Molecular Medicine and Medical Biotechnologies, School of Medicine, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","article-title":"A multi-source approach to determine SMA incidence and research ready population","volume":"264","author":"Verhaart","year":"2017","journal-title":"J. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1212\/WNL.0000000000201654","article-title":"Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey","volume":"100","author":"Coratti","year":"2023","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Nishio, H., Niba, E.T.E., Saito, T., Okamoto, K., Takeshima, Y., and Awano, H. (2023). Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241511939"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Faravelli, I., Riboldi, G.M., Rinchetti, P., and Lotti, F. (2023). The SMN Complex at the Crossroad between RNA Metabolism and Neurodegeneration. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032247"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Butchbach, M.E.R. (2016). Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. Front. Mol. Biosci., 3.","DOI":"10.3389\/fmolb.2016.00007"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lejman, J., Zieli\u0144ski, G., Gawda, P., and Lejman, M. (2021). Alternative Splicing Role in New Therapies of Spinal Muscular Atrophy. Genes, 12.","DOI":"10.3390\/genes12091346"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TACG.S239603","article-title":"Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance","volume":"14","author":"Keinath","year":"2021","journal-title":"Appl. Clin. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Davidson, J.E., Russell, J.S., Martinez, N.N., Mowat, D.R., Jones, K.J., Kirk, E.P., Kariyawasam, D., Farrar, M., and D\u2019silva, A. (2023). The Carrier Frequency of Two SMN1 Genes in Parents of Symptomatic Children with SMA and the Significance of SMN1 Exon 8 in Carriers. Genes, 14.","DOI":"10.3390\/genes14071403"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.braindev.2008.08.012","article-title":"Combination of SMN2 copy number and NAIP deletion predicts disease severity in spinal muscular atrophy","volume":"31","author":"Watihayati","year":"2009","journal-title":"Brain Dev."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Blasco-P\u00e9rez, L., Costa-Roger, M., Leno-Colorado, J., Bernal, S., Alias, L., Codina-Sol\u00e0, M., Mart\u00ednez-Cruz, D., Castiglioni, C., Bertini, E., and Travaglini, L. (2022). Deep Molecular Characterization of Milder Spinal Muscular Atrophy Patients Carrying the c.859G>C Variant in SMN2. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158289"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100899","DOI":"10.1016\/j.spen.2021.100899","article-title":"Spinal Muscular Atrophy Treatments, Newborn Screening, and the Creation of a Neurogenetics Urgency","volume":"38","author":"Butterfield","year":"2021","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102967","DOI":"10.1016\/j.eclinm.2024.102967","article-title":"Type I spinal muscular atrophy and disease modifying treatments: A nationwide study in children born since 2016","volume":"78","author":"Pera","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Varone, A., Esposito, G., and Bitetti, I. (2025). Spinal muscular atrophy in the era of newborn screening: How the classification could change. Front. Neurol., 16.","DOI":"10.3389\/fneur.2025.1542396"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Cooper, K., Nalbant, G., Sutton, A., Harnan, S., Thokala, P., Chilcott, J., McNeill, A., and Bessey, A. (2024). Systematic Review of Newborn Screening Programmes for Spinal Muscular Atrophy. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10030049"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Angilletta, I., Ferrante, R., Giansante, R., Lombardi, L., Babore, A., Dell\u2019Elice, A., Alessandrelli, E., Notarangelo, S., Ranaudo, M., and Palmarini, C. (2023). Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914873"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jmg-2022-108873","article-title":"Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: Towards specific guidelines and standard operating procedures for the molecular diagnosis","volume":"60","author":"Abiusi","year":"2023","journal-title":"J. Med. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/acn3.52018","article-title":"Early spinal muscular atrophy treatment following newborn screening: A 20-month review of the first Italian regional experience","volume":"11","author":"Gagliardi","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13023-025-03546-1","article-title":"Combined biochemical profiling and DNA sequencing in the expanded newborn screening for inherited metabolic diseases: The experience in an Italian reference center","volume":"20","author":"Fecarotta","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gutierrez-Mateo, C., Timonen, A., Vaahtera, K., Jaakkola, M., Hougaard, D.M., Bybjerg-Grauholm, J., Baekvad-Hansen, M., Adamsen, D., Filippov, G., and Dallaire, S. (2019). Development of a Multiplex Real-Time PCR Assay for the Newborn Screening of SCID, SMA, and XLA. Int. J. Neonatal Screen., 5.","DOI":"10.3390\/ijns5040039"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jmoldx.2021.03.004","article-title":"Multisite Evaluation and Validation of a Sensitive Diagnostic and Screening System for Spinal Muscular Atrophy that Reports SMN1 and SMN2 Copy Number, along with Disease Modifier and Gene Duplication Variants","volume":"23","author":"Milligan","year":"2021","journal-title":"J. Mol. Diagn. JMD"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Milligan, J.N., Blasco-P\u00e9rez, L., Costa-Roger, M., Codina-Sol\u00e0, M., and Tizzano, E.F. (2022). Recommendations for Interpreting and Reporting Silent Carrier and Disease-Modifying Variants in SMA Testing Workflows. Genes, 13.","DOI":"10.3390\/genes13091657"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Brku\u0161anin, M., Garai, N., Karanovi\u0107, J., \u0160ljivan\u010danin Jakovljevi\u0107, T., Dimitrijevi\u0107, A., Jovanovi\u0107, K., Mitrovi\u0107, T.L., Mikovi\u0107, \u017d., Braju\u0161kovi\u0107, G., and Nikoli\u0107, D.M. (2024). Our Journey from Individual Efforts to Nationwide Support: Implementing Newborn Screening for Spinal Muscular Atrophy in Serbia. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10030057"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/gim.2017.152","article-title":"Pilot study of population-based newborn screening for spinal muscular atrophy in New York state","volume":"20","author":"Kraszewski","year":"2018","journal-title":"Genet. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/ajmg.a.33474","article-title":"Newborn and carrier screening for spinal muscular atrophy","volume":"152A","author":"Prior","year":"2010","journal-title":"Am. J. Med. genetics. Part A"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.braindev.2020.09.005","article-title":"Clinical phenotypes of spinal muscular atrophy patients with hybrid SMN gene","volume":"43","author":"Niba","year":"2021","journal-title":"Brain Dev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Yao, M., Jiang, L., Yu, Y., Cui, Y., Chen, Y., Zhou, D., Gao, F., and Mao, S. (2024). Optimized MLPA workflow for spinal muscular atrophy diagnosis: Identification of a novel variant, NC_000005.10:g.(70919941_70927324)del in isolated exon 1 of SMN1 gene through long-range PCR. BMC Neurol., 24.","DOI":"10.1186\/s12883-024-03592-5"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.nmd.2023.11.013","article-title":"Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium","volume":"34","author":"Dangouloff","year":"2024","journal-title":"Neuromuscul. Disord. NMD"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.nmd.2023.12.008","article-title":"270th ENMC International Workshop: Consensus for SMN2 genetic analysis in SMA patients 10\u201312 March, 2023, Hoofddorp, the Netherlands","volume":"34","author":"Abiusi","year":"2024","journal-title":"Neuromuscul. Disord. NMD"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ejmg.2015.11.006","article-title":"Carrier testing in children and adolescents","volume":"58","author":"Vears","year":"2015","journal-title":"Eur. J. Med. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1515\/cclm-2013-0209","article-title":"Prenatal molecular diagnosis of inherited neuromuscular diseases: Duchenne\/Becker muscular dystrophy, myotonic dystrophy type 1 and spinal muscular atrophy","volume":"51","author":"Esposito","year":"2013","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMc2300802","article-title":"Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy","volume":"392","author":"Finkel","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"British Medical Association (2012). Medical Ethics Today: The BMA\u2019s Handbook of Ethics and Law, Chapter 9 (pp 365\u2013413), Genetics. Carrier testing of children (pp 379\u2013383); Wiley.","DOI":"10.1002\/9781444355666.ch9"}],"container-title":["International Journal of Neonatal Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2409-515X\/11\/3\/64\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:29:33Z","timestamp":1760034573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2409-515X\/11\/3\/64"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,17]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijns11030064"],"URL":"https:\/\/doi.org\/10.3390\/ijns11030064","relation":{},"ISSN":["2409-515X"],"issn-type":[{"value":"2409-515X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,17]]}}}